Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor

被引:290
|
作者
Hu, Huimin [1 ]
Mu, Quanhua [2 ,12 ]
Bao, Zhaoshi [1 ,4 ]
Chen, Yiyun [3 ,12 ]
Liu, Yanwei [1 ,5 ]
Chen, Jing [1 ]
Wang, Kuanyu [1 ]
Wang, Zheng [1 ]
Nam, Yoonhee [3 ]
Jiang, Biaobin [2 ,3 ,13 ]
Sa, Jason K. [10 ]
Cho, Hee-Jin [10 ]
Her, Nam-Gu [10 ]
Zhang, Chuanbao [4 ]
Zhao, Zheng [1 ]
Zhang, Ying [1 ]
Zeng, Fan [1 ]
Wu, Fan [1 ]
Kang, Xun [6 ]
Liu, Yuqing [1 ]
Qian, Zenghui [1 ]
Wang, Zhiliang [1 ]
Huang, Ruoyu [1 ]
Wang, Qiangwei [1 ]
Zhang, Wei [4 ]
Qiu, Xiaoguang [5 ]
Li, Wenbin [6 ]
Nam, Do-Hyun [10 ,11 ]
Fan, Xiaolong [7 ]
Wang, Jiguang [2 ,3 ,12 ]
Jiang, Tao [1 ,4 ,8 ,9 ]
机构
[1] Capital Med Univ, Beijing Neurosurg Inst, Beijing 100050, Peoples R China
[2] Hong Kong Univ Sci & Technol, Dept Chem & Biol Engn, Hong Kong, Hong Kong, Peoples R China
[3] Hong Kong Univ Sci & Technol, Div Life Sci, Hong Kong, Hong Kong, Peoples R China
[4] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing 100050, Peoples R China
[5] Capital Med Univ, Beijing Tiantan Hosp, Dept Radiotherapy, Beijing 100050, Peoples R China
[6] Capital Med Univ, Beijing Shijitan Hosp, Dept Oncol, Beijing 100050, Peoples R China
[7] Beijing Normal Univ, Lab Neurosci & Brain Dev, Beijing Key Lab Gene Resource & Mol Dev, Beijing 100875, Peoples R China
[8] Beijing Inst Brain Disorders, Ctr Brain Tumor, Beijing 100069, Peoples R China
[9] China Natl Clin Res Ctr Neurol Dis, Beijing 100050, Peoples R China
[10] Samsung Med Ctr, Inst Refractory Canc Res, Seoul, South Korea
[11] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Neurosurg, Seoul, South Korea
[12] Hong Kong Univ Sci & Technol, Ctr Syst Biol & Human Hlth, Hong Kong, Hong Kong, Peoples R China
[13] Hong Kong Univ Sci & Technol, Inst Adv Study, Hong Kong, Hong Kong, Peoples R China
基金
中国国家自然科学基金;
关键词
RNA-SEQ; GENOMIC CHARACTERIZATION; REVEALS; EVOLUTION; GLIOMAS; GENE; CHEMORESISTANCE; ARCHITECTURE; PROGRESSION; ACTIVATION;
D O I
10.1016/j.cell.2018.09.038
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Low-grade gliomas almost invariably progress into secondary glioblastoma (sGBM) with limited therapeutic option and poorly understood mechanism. By studying the mutational landscape of 188 sGBMs, we find significant enrichment of TP53 mutations, somatic hypermutation, MET-exon-14-skipping (METex14), PTPRZ1-MET (ZM) fusions, and MET amplification. Strikingly, METex14 frequently co-occurs with ZM fusion and is present in similar to 14% of cases with significantly worse prognosis Subsequent studies show that METex14 promotes glioma progression by prolonging MET activity. Furthermore, we describe a MET kinase inhibitor, PLB-1001, that demonstrates remarkable potency in selectively inhibiting MET-altered tumor cells in pre-clinical models. Importantly, this compound also shows blood-brain barrier permeability and is subsequently applied in a phase I clinical trial that enrolls MET-altered chemo-resistant glioma patients. Encouragingly, PLB-1001 achieves partial response in at least two advanced sGBM patients with rarely significant side effects, underscoring the clinical potential for precisely treating gliomas using this therapy.
引用
收藏
页码:1665 / +
页数:32
相关论文
共 50 条
  • [41] Molecular Markers Impacting Survival in Patients Receiving Concurrent Chemoradiation and Tumor-Treating Fields (TTF) in Patients with Newly Diagnosed Glioblastoma: Secondary Analysis of SPARE Trial
    Cappelli, L.
    Kanyne, A.
    Poiset, S. J.
    Ali, A.
    Miller, R. C.
    Niazi, M. Z. K.
    Alnahhas, I.
    Shi, W.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E68 - E69
  • [42] Molecular markers impacting survival in patients receiving concurrent chemoradiation and Tumor-Treating Fields (TTF) in patients with newly diagnosed glioblastoma: secondary analysis of SPARE trial
    Kayne, Allison
    Poiset, Spencer
    Ali, Ayesha
    Miller, Ryan
    Niazi, Muneeb
    Cappelli, Louis
    Alnahhas, Iyad
    Shi, Wenyin
    NEUROLOGY, 2023, 100 (17)
  • [43] A phase II clinical trial to test the efficacy of DCVax-brain, autologous dendritic cells pulsed with autologous tumor lysate, for the treatment of patients with glioblastoma multiforme
    Bosch, Marnix
    Boynton, Alton
    Prins, Robert
    Liau, Linda
    NEURO-ONCOLOGY, 2007, 9 (04) : 509 - 509
  • [44] Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
    Ahluwalia, Manmeet S.
    Ozair, Ahmad
    Drappatz, Jan
    Ye, Xiaobu
    Peng, Sen
    Lee, Matthew
    Rath, Sanhita
    Dhruv, Harshil
    Hao, Yue
    Berens, Michael E.
    Walbert, Tobias
    Holdhoff, Matthias
    Lesser, Glenn J.
    Cloughesy, Timothy F.
    Sloan, Andrew E.
    Takebe, Naoko
    Couce, Marta
    Peereboom, David M.
    Nabors, Burt
    Wen, Patrick Y.
    Grossman, Stuart A.
    Rogers, Lisa R.
    CLINICAL CANCER RESEARCH, 2024, 30 (15) : 3167 - 3178
  • [45] Low-grade astrocytoma, anaplastic oligodendroglioma or astrocytoma, and glioblastoma: The clinical trial portfolio of the EORTC Brain Tumor and Radiation Oncology Groups for newly diagnosed patients.
    Baumert, B.
    Stupp, R.
    Van den Bent, M. J.
    Erridge, A.
    Brandes, A.
    Pesce, G. A.
    Weber, D. C.
    Lacombe, D. A.
    Gorlia, T.
    Wick, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [46] NEUROCOGNITIVE OUTCOMES OF EORTC BRAIN TUMOR GROUP STUDY 26101 PHASE III TRIAL COMPARING THE COMBINATION OF LOMUSTINE AND BEVACIZUMAB WITH LOMUSTINE ALONE IN GLIOBLASTOMA PATIENTS WITH FIRST PROGRESSION
    Klein, Martin
    Reijneveld, Jaap C.
    Idbaih, Ahmed
    Brandes, Alba
    Taal, Walter
    Clement, Paul M.
    Domont, Julien
    Campone, Mario
    Taphoorn, Martin J. B.
    Stupp, Roger
    Fabbro, Michel
    Le Rhun, Emilie
    Dubois, Francois
    Weller, Michael
    Golfinopoulos, Vassilis
    Platten, Michael
    Gorlia, Thierry
    van den Bent, Martin
    Wick, Wolfgang
    NEURO-ONCOLOGY, 2017, 19 : 142 - 142
  • [47] Standard chemoradiotherapy ± cilengitide in newly diagnosed glioblastoma (GBM): Updated results and subgroup analyses of the international randomized phase III CENTRIC trial (EORTC trial #26071-22072/Canadian Brain Tumor Consortium)
    Stupp, R.
    Hegi, M. E.
    Gorlia, T.
    Perry, J. R.
    Erridge, S.
    Reardon, D. A.
    Markivskyy, A.
    Wick, W.
    Hong, Y. K.
    Weller, M.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S775 - S775
  • [48] MANAGING CANCER AND LIVING MEANINGFULLY (CALM) IN PRIMARY AND SECONDARY MALIGNANT BRAIN TUMOR PATIENTS: INTERIM ANALYSIS OF A PHASE IIC RANDOMIZED CONTROL PILOT TRIAL
    Loughan, Ashlee
    Lanoye, Autumn
    Davies, Alexandria
    Kleva, Chris
    Zarrella, Giuliana
    Fox, Amber
    Rodin, Gary
    NEURO-ONCOLOGY, 2024, 26
  • [49] Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial
    Kickingereder, Philipp
    Brugnara, Gianluca
    Hansen, Mikkel Bo
    Nowosielski, Martha
    Pflueger, Irada
    Schell, Marianne
    Isensee, Fabian
    Foltyn, Martha
    Neuberger, Ulf
    Kessler, Tobias
    Sahm, Felix
    Wick, Antje
    Heiland, Sabine
    Weller, Michael
    Platten, Michael
    von Deimling, Andreas
    Maier-Hein, Klaus H.
    Ostergaard, Leif
    van den Bent, Martin J.
    Gorlia, Thierry
    Wick, Wolfgang
    Bendszus, Martin
    RADIOLOGY, 2020, 297 (01) : 164 - 175
  • [50] Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group
    Stupp, R.
    Tosoni, A.
    Bromberg, J. E. C.
    Hau, P.
    Campone, M.
    Gijtenbeek, J.
    Frenay, M.
    Breimer, L.
    Wiesinger, H.
    Allgeier, A.
    van den Bent, M. J.
    Bogdahn, U.
    van der Graaf, W.
    Yun, H. J.
    Gorlia, T.
    Lacombe, D.
    Brandes, A. A.
    ANNALS OF ONCOLOGY, 2011, 22 (09) : 2144 - 2149